Serum hemorphin-7 levels are decreased in obesity

Authors

  • Marie Maraninchi,

    1. Aix Marseille Université, Inserm, INRA, NORT UMR_1062, Marseille, France
    2. APHM, Timone Hospital, Nutrition, Metabolic Diseases and Endocrinology Department, Marseille, France
    Search for more papers by this author
  • Delphine Feron,

    1. University of La Rochelle, CNRS-URL, LIENSS UMR 7266, AMES team, Pole of Science and Technology, La Rochelle, France
    Search for more papers by this author
  • Ingrid Fruitier-Arnaudin,

    1. University of La Rochelle, CNRS-URL, LIENSS UMR 7266, AMES team, Pole of Science and Technology, La Rochelle, France
    Search for more papers by this author
  • Audrey Bégu-Le Corroller,

    1. Aix Marseille Université, Inserm, INRA, NORT UMR_1062, Marseille, France
    2. APHM, Timone Hospital, Nutrition, Metabolic Diseases and Endocrinology Department, Marseille, France
    Search for more papers by this author
  • Juan P. Nogueira,

    1. Aix Marseille Université, Inserm, INRA, NORT UMR_1062, Marseille, France
    2. APHM, Timone Hospital, Nutrition, Metabolic Diseases and Endocrinology Department, Marseille, France
    Search for more papers by this author
  • Julien Mancini,

    1. Aix Marseille Université, Inserm, IRD, SESSTIM, UMR 912, Marseille, France
    2. APHM, Timone Hospital, Public Health Department, Marseille, France
    Search for more papers by this author
  • René Valéro,

    1. Aix Marseille Université, Inserm, INRA, NORT UMR_1062, Marseille, France
    2. APHM, Timone Hospital, Nutrition, Metabolic Diseases and Endocrinology Department, Marseille, France
    Search for more papers by this author
  • Jean M. Piot,

    1. University of La Rochelle, CNRS-URL, LIENSS UMR 7266, AMES team, Pole of Science and Technology, La Rochelle, France
    Search for more papers by this author
  • Bernard Vialettes

    Corresponding author
    1. Aix Marseille Université, Inserm, INRA, NORT UMR_1062, Marseille, France
    2. APHM, Timone Hospital, Nutrition, Metabolic Diseases and Endocrinology Department, Marseille, France
    • Aix Marseille Université, Inserm, INRA, NORT UMR_1062, Marseille, France; APHM, Timone Hospital, Nutrition, Metabolic Diseases and Endocrinology Department, Marseille, France;
    Search for more papers by this author
    • The first two authors contributed equally to the work.


Abstract

Objective:

Hemorphin peptides exhibit biological activities that interfere with the endorphin system, the inflammatory response, and blood-pressure control. VV-hemorphin-7 and LVV-hemorphin-7 peptides exert a hypotensive effect, in particular, by inhibiting the renin–angiotensin system. Furthermore, levels of circulating hemorphin-7 peptides have been found to be decreased in diseases such as type 1 and type 2 diabetes.

Design and Methods:

Because type 2 diabetes and obesity share common features, such as insulin resistance, microinflammation, high glomerular-filtration rate (GFR), and cardiovascular risk, we evaluated serum VV-hemorphin-7 like immunoreactivity (VVH7-i.r.) levels, using an enzyme-linked immunosorbent assay method, on a group of 54 obese subjects without diabetes or hypertension, compared with a group of 33 healthy normal-weight subjects.

Results:

Circulating VVH7-i.r. levels were significantly decreased in the obese group compared with the control group (1.98 ± 0.19 vs. 4.86 ± 0.54 µmol/l, respectively, P < 0.01), and a significant negative correlation between VVH7-i.r. and diastolic blood pressure (DBP) was found in obese patients (r = −0.35, P = 0.011). There was no significant correlation between VVH7-i.r. level and insulin resistance, metabolic syndrome, or GFR.

Conclusions:

The decreased serum hemorphin-7 found in obese subjects, as in diabetes, may contribute to the development of hypertension and to the cardiovascular risk associated with these metabolic diseases.

Ancillary